SCHEMBL15520293

SCHEMBL15520293

CC(=O)Nc1ccc2ncnc(Cl)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.60
MAP4K4 O95819 2/20 0.52
ABCG2 Q9UNQ0 1/20 0.51
ERBB2 P04626 2/20 0.49
LCK P06239 1/20 0.49
KDM4E B2RXH2 3/20 0.49
RAB9A P51151 3/20 0.49
MAPT P10636 3/20 0.49
MEN1 O00255 2/20 0.49
NPC1 O15118 2/20 0.49
KMT2A Q03164 2/20 0.49
PABPC1 P11940 1/20 0.49
AKT1 P31749 1/20 0.48
GLA P06280 1/20 0.47
TNNI3 P19429 1/20 0.47
TNNT2 P45379 1/20 0.47
TNNC1 P63316 1/20 0.47
RUNX1 Q01196 1/20 0.47
CBFB Q13951 1/20 0.47
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3335124 0.89 MAP4K4 (0.57) EGFRMAP4K4ABCG2KDM4ERAB9A
SCHEMBL28389700 0.82 EGFR (0.61) EGFRERBB2
SCHEMBL6589963 0.82 EGFR (0.60) EGFRABCG2ERBB2MEN1KMT2A
SCHEMBL27748903 0.81 EGFR (0.64) EGFRERBB2
SCHEMBL28806345 0.80 SLC2A1 (0.53) EGFRMAP4K4KDM4ERAB9AMEN1
SCHEMBL1372765 0.79 EGFR (0.61) EGFRERBB2
SCHEMBL6468321 0.79 EGFR (0.54) EGFRERBB2LCKKDM4ERAB9A
SCHEMBL8871003 0.77 EGFR (0.76) EGFRABCG2ERBB2KDM4EMAPT
SCHEMBL27758510 0.76 EGFR (0.76) EGFRABCG2ERBB2LCKKDM4E
Acetic Acid SCHEMBL3160960 0.75 PDE4A (0.44) EGFRMAP4K4ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102775356-B 4-aminoquinazoline derivative and application thereof JIANGSU HENGYI PHARMACEUTICAL CO LTD 2015-07-22 CN disclosed
US-9034886-B2 4-aminoquinazoline derivatives and uses thereof SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2015-05-19 US disclosed
US-20140235633-A1 4-Aminoquinazoline Derivatives and Uses Thereof SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2014-08-21 US disclosed
EP-2708532-A1 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) 2014-03-19 EP disclosed
CN-102775356-A 4-aminoquinazoline derivative and application thereof JIANGSU HENGYI PHARMACEUTICAL CO LTD 2012-11-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235633-A1 4-Aminoquinazoline Derivatives and Uses Thereof HDAC5, HDAC4, HDAC1 EGFR 3198/4885MAP4K4 296/4885ABCG2 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.